Objective: The critical window hypothesis of hormone therapy (HT) and cognitive function states that the effects of HT depend on timing of initiation with respect to age, the menopausal transition, or both, and that optimal effects are evident with early initiation. This article reviews clinical studies that bear on this hypothesis.
A lzheimer's disease (AD) is now the sixth leading cause of death in the United States, 1 with approximately 5.4 million individuals having the disease. 2 Of the top 10 leading causes of death in the United States, AD shows the greatest sex difference, with more women than men dying of the disease. 3 A recent study of age-adjusted mortality rates from AD between 1999 and 2008 demonstrated that 20% more women than men died of the disease. 4 There is debate about whether this sex difference in the prevalence of AD is attributable to the greater longevity of women compared with men. Evidence against that explanation comes from an analysis of data pooled from four population-based studies showing a greater incidence of AD in women compared with men; the cumulative risk of developing AD at the age of 95 years was 0.22 for 65-year-old women compared with 0.09 for men. 5 The prevalence of AD is expected to triple by 2050, with an estimated cost of US$20 trillion, including US$11.4 trillion in costs to Medicare and US$3.6 trillion in costs to Medicaid. 6 In light of the enormous costs associated with the disease, a medication that delays the onset of the disease by just 5 years would be associated with significant cost savings. Conversely, a medication that hastens the onset of the disease would be associated with significant costs. No medication specifically prescribed for women has received greater attention in the field of AD research than hormone therapy (HT).
This review focuses on clinical studies bearing on the critical window hypothesis of HT and cognition. The critical window hypothesis, also known as the timing hypothesis or the critical period hypothesis, says that the effects of HT depend on the timing of initiation of treatment with respect to age, onset of menopause, or both, with benefits limited to early initiation. 7, 8 This review first describes epidemiological studies that gave rise to the hypothesis that HT might impact the risk of AD. The history of studies that gave rise to the timing hypothesis is reviewed and shows that the hypothesis preceded later findings from the Women's Health Initiative Memory Study (WHIMS). 9, 10 Challenges in conducting a randomized controlled trial of early HT for AD prevention are described to justify a focus on observational studies of AD and randomized trials of verbal memory. Three observational studies of AD that specifically examined the timing hypothesisVeach providing support for the hypothesisVare reviewed. Four observational studies that examined the timing hypothesis on cognitive tests are described. Together, they show mixed results. Next, randomized clinical trials of HT and verbal memory are summarized based on evidence that verbal memory is a suitable proxy outcome for AD risk. Those data provide tentative support for the benefits of early use of estrogen alone and mixed findings with respect to the use of estrogen plus progestin. Lastly, neuroimaging studies that bear on the critical window hypothesis and show initial evidence for the enhanced function of the hippocampus and prefrontal cortex in early users are reviewed. An evaluation of the body of evidence included in this review concludes that the literature generally provides support for the critical window hypothesis. Future directions and research priorities are briefly discussed.
OBSERVATIONAL STUDIES OF HT AND AD
The typical pattern of HT use in the United States includes initiation of HT close in time to the final menstrual period and use of estrogen alone, most typically conjugated equine estrogens (CEE). For this reason, it is appropriate to review observational studies of the risks of HT and AD when evaluating the critical window hypothesis. To date, there have been 18 observational studies examining the association between ever use of HT and AD. Fourteen of those studies were retrospective case-control studies in which individuals with AD were matched to controls and exposure to HT was ascertained retrospectively 11<19 or prospectively. 20<24 Four were prospective studies in which women were followed over time and the outcome measure was incident AD.
25<28 Meta-analyses of these studies demonstrated a significant reduction (29%-44%) 29<32 in the risk of AD among women who used HT compared with women who did not use HT. Notably, none of the studies demonstrated a significant increase in the risk of AD with HT. A significant limitation of those studies, however, was the Bhealthy user bias[; compared with women who did not use HT, women who used HT were healthier (particularly in relation to cardiovascular risk factors) and better educated. Because better cardiovascular health and higher educational status protect against AD, it was unclear whether it was truly the HT or, alternatively, the biases in the characteristics of women who went on HT that explained the findings.
EMERGENCE OF THE CRITICAL
WINDOW HYPOTHESIS In 2000, while WHIMS was in progress, findings from three randomized placebo-controlled clinical trials of estrogen therapy for the treatment of women with AD were published. 33<35 None of the trials showed efficacy. One trial examined CEE 1.25 mg/day in 42 women followed for 16 weeks 33 ; another trial examined CEE 0.625 or 1.25 mg/day in 120 women followed for 15 months 34 ; and a third trial examined 1.25 mg of CEE in 50 women followed for 12 weeks. 35 An editorial by Marder et al 36 that accompanied the last of those trials 33 noted the discrepancy between the findings from treatment trials and the findings from observational studies and suggested that BPerhaps critical periods occur at menopause, when withdrawal of hormonal influence leads to increased brain susceptibility to pathologic processes[ and that Bperimenopause or immediately postmenopause might be the appropriate time for intervention. [ 7 The possibility that timing of initiation was a potential modifier of the effect of HT on cognitive function gained additional momentum with a 2002 publication from the Cache County Study. 27 That observational study was the first to stratify the use of HT by current versus former use and, within those strata, by duration of treatment. In agreement with previous observational studies, the overall finding was a reduced risk of AD among women who had used HT compared with those who had not. The new and striking finding was that, compared with women who never used HT, former users of HT showed a reduced risk of AD, but current users did not. Among current users, only those who had used HT for 10 years or more showed a reduced risk. Given that the average age of women in that study was 73 years, the implication was that HT might be ineffective in reducing the risk of dementia in the latent preclinical stage of the disease but might be effective if initiated earlier. An accompanying editorial by Resnick and Henderson 8 noted, BBecause many women use HT for relatively brief durations around the menopause, the protective effect of ever-use therapy suggests the possibility of a critical period during the climacteric years, which are characterized by relatively rapid estrogen depletion. [ In 2003, the primary findings from WHIMS were published. 10 WHIMS remains the only randomized placebocontrolled study of the effect of HT on the risk for dementia. The study had two arms: one arm for hysterectomized women where the active treatment was CEE alone, and the other arm for women with intact uterus where the active treatment was CEE plus medroxyprogesterone acetate (MPA). The focus on those types of HT was clinically relevant because they were the most commonly used clinically at the time the Women's Health Initiative (WHI) was launched. In studying the hypothesis that HT was effective in the primary prevention of late-life AD, it was necessary to study women who were at risk for incident AD during the course of the study. Women enrolled in WHIMS therefore were 65 years or older at the time of enrollment. From a public health perspective, it was thought that those women had the most to gain from the intervention because they were the most vulnerable to developing the disease, and no previous study had suggested any increase in the risk of AD among women who were taking HT after the age of 65 years.
The findings from WHIMS were in striking contrast to the findings from the observational studies but were consistent with the Cache County Study 27 and with the lack of efficacy in women with AD. 33<35 In the CEE/MPA arm, with a sample size of 4,532 women, there was a doubling of the risk of allcause dementia with active treatment compared with placebo after an average follow-up of 4 years. 10 The short time frame during which the increased risk for all-cause dementia emerged suggested that the increased risk of dementia did not reflect the primary initiation of neuropathology but rather hastened existing neuropathology. Although AD was the initial primary outcome variable and although most dementia cases in WHIMS participants were attributable to AD, there were too few cases of AD when the study was prematurely halted owing to other risks; thus, all-cause dementia became the primary outcome. Findings from the CEE-alone armVwith a sample size of 2,947 women followed for an average of 5 yearsVpublished in 2004 found no significant impact of CEE on dementia risk. 9 A direct comparison between the two arms of the study, however, revealed no statistical difference in dementia risk. 9 Based on this, WHIMS investigators did not distinguish between the effects of CEE and the effects of CEE/MPA.
One of the leading hypotheses explaining the increased risk of dementia with CEE/MPA was increased ischemic burden that hastened the development of dementia. 9 Autopsy data from the Nun Study had shown that, given two clinical cases with equal burdens of AD neuropathology, the one with brain infarcts would exhibit poorer cognitive performance and would be more likely to present with dementia than the one without infarcts. 37 In the WHI, CEE/MPA increased the risk of ischemic stroke by 30%. 38 It therefore seemed plausible that CEE/MPA might have increased subclinical cerebral vascular disease, which in turn increased the risk of dementia. Findings from the WHIMS Magnetic Resonance Imaging (MRI) Study, however, did not support that explanation; in a subsample of 1,403 WHIMS participants, there was no difference in the volume of ischemic lesions between those who had been randomized to receive active treatment and those who had been randomized to receive placebo. 39 Despite a large sample size and the use of strong imaging methods, the WHIMS-MRI Study was not fully able to examine the impact of CEE/MPA on subclinical cerebrovascular disease because assessments of ischemic load were conducted, on average, 7 years after the participants initiated treatment. Although the sample size in the WHIMS-MRI Study was large, it is not possible to entirely rule out the possibility that groups differed in ischemic load at baseline or that CEE/MPA led to increases in ischemic volume early after treatment initiation. Notably, the key finding from the WHIMS-MRI Study was that women in the active treatment arm showed smaller brain volumes in the frontal lobe and hippocampus compared with women in the placebo arm. 40 Furthermore, loss of hippocampal volume was most pronounced in those women who showed the poorest performance on a screening test for cognitive impairment before randomization to HT. 40 Later publications linked the loss of brain volume to the diagnosis of dementia in WHIMS. 41 These results suggested that HT was detrimental to older women who initiated HT when they were beginning to experience cognitive decline.
CHALLENGES IN TESTING THE CRITICAL WINDOW HYPOTHESIS FOR AD PREVENTION
A decade since the publication of WHIMS, there has been considerable debate about the external generalizability of WHIMS findings to perimenopausal and younger postmenopausal women and, therefore, about the clinical significance of WHIMS findings to more typical patterns of HT use. Before the WHI, 85% of women in the United States who initiated HT did so within 1 year of the final menstrual period. It was therefore possible that the discrepancy between the positive observational studies and the negative findings from WHIMS might be attributable to differences in the timing of treatment with respect to age, final menstrual period, or both. Testing this hypothesis using a randomized placebo-controlled trial is not feasible because such a study would require (1) randomization of a large sample of perimenopausal or early postmenopausal women (WHIMS had 97,500 women), (2) longitudinal follow-up for more than 20 years (until they were 65 y or older), (3) sufficient adherence, and (4) sufficient funding. Furthermore, the clinical relevance of such a study might be limited by changes in the doses and types of menopausal treatments used in the next decades, including the use of new progestins, new selective estrogen receptor modulators (SERMs), and tissuespecific estrogen complexes.
The obstacles in conducting a clinical trial to test the timing hypothesis for AD prevention necessitate that evidence from other clinical research designs be examined to evaluate the hypothesis. BObservational studies of HT timing and risk for AD[ reviews findings from such studies, including observational studies that have examined the impact of the timing of initiation of HT on AD risk and cognitive performance; randomized clinical trials of HT and verbal memory; and neuroimaging studies.
OBSERVATIONAL STUDIES OF HT TIMING
AND RISK FOR AD To date, there have been three observational studies of the impact of the timing of initiation of HT on the risk for dementia. All three found support for the hypothesis. The first was a case-control study (n = 426 women with AD, 545 relatives without dementia) from the Multi-Institutional Research in Alzheimer's Genetic Epidemiology (MIRAGE) study, which examined the risks of AD based on the age at which women initiated HT. 19 Only women in the youngest age tertile (aged 50-63 y) showed a reduced risk of AD. The second was a prospective observational study from Kaiser Permanente (n = 5,504 women, including 1,524 women with AD). 42 Women who used HT only at midlife showed a 26% reduced risk of AD; those who used HT only at late life showed a 46% increased risk of dementia; and those who used HT during both periods showed neutral risk. The third study was a follow-up study from the Cache County Study, 27 where data were stratified by timing of initiation (n = 1,768, including 174 women with AD). There the results depended not only on the timing of initiation but also on whether women used estrogen alone or estrogen in combination with a progestin. Women who initiated HT within 5 years of menopause onset showed a 30% reduced risk of AD, and the magnitude of risk was lowest for women who initiated HT early and continued to use HT for 10 years (37% reduced risk). Those who initiated HT later showed no protection, and those who initiated combination estrogen-plus-progestin therapy later in life showed a nearly twofold increase in risk, although that effect was a trend. Overall, observational studies of AD showed reliable support for the critical window hypothesis. Also, the studies provided evidence that late-life initiation of HT increases the risk of AD.
VERBAL MEMORY AS A CLINICALLY
SIGNIFICANT OUTCOME Neuropsychological tests of verbal memory involve learning and recall of word lists, paragraphs, and stories. These tests are clinically useful because they have known normative standards and clinical validity in predicting dementia. A metaanalysis of 32 clinical trials of HT demonstrated that the cognitive domain most sensitive to the effects of HT (positive or negative) is verbal memory. 43 The clinical relevance of this effect is high because deficits in verbal learning and memory have been shown to be a very strong predictor of individuals who will develop dementia. 44<46 Notably, women show a lifelong advantage in this cognitive domain compared with men; unlike men, women begin to show declines with age only after the age of 55 years. 47, 48 Studies specifically examining verbal memory during the menopausal transition indicate that women show subtle deficits in verbal memory as they transition through menopause. 49, 50 Findings from an ancillary study to WHIMS, the Women's Health Initiative Study of Cognitive Aging (WHISCA), provide perhaps the strongest justification for focusing on verbal memory as a clinically relevant primary outcome. Whereas WHIMS focused on dementia outcomes, WHISCA focused on age-related changes in cognitive test performance. 51 CEE/ MPA increased the risk for dementia in WHIMS 10 and, as will be described in more detail later, CEE/MPA decreased verbal memory in WHISCA. 52 CEE alone had no impact on dementia in WHIMS, 9 and CEE alone had no impact on verbal memory in WHISCA. 53 This pattern of results suggests that verbal memory may be a good proxy for dementia risk when evaluating the critical window hypothesis. Findings from WHISCA underscore the importance of distinguishing not only between timing of initiation but also between estrogen alone and estrogen plus a progestogen.
OBSERVATIONAL STUDIES OF HT TIMING AND
COGNITIVE PERFORMANCE Most women initiate HT within the Bwindow[; therefore, most observational studies reflect early initiation. A metaanalysis of observational studies concluded that HT positively impacts verbal memory function as measured by paragraph recall and word lists, but the levels of heterogeneity across studies and inconsistency across tests of verbal memory (even within the same study) are too great to draw any firm conclusions. 30 The present investigation identified relevant articles for inclusion based on PubMed searches (key words Bmemory,[ Bdementia,[ Bcognition,[ BAlzheimer's disease,[ Bestrogen,[ Bestradiol,[ Bhormone therapy,[ and Bhormone replacement therapy[) and by searching reference sections from identified studies and review articles. For the review of articles addressing the timing hypothesis, the search terms Btiming,[ Bcritical window,[ and Bcritical period[ were used, and the reference sections of those articles were reviewed for additional articles. In the review of studies of verbal memory, only those studies using standardized neuropsychological measures of memory performance were included; studies using nonstandardized experimental measures of memory performance were not included. In addition, for the review of randomized trials, only studies with a placebo-controlled arm were included, and the minimal treatment duration was 2 weeks.
Four prospective observational studies have directly examined the impact of the timing of initiation of HT on standardized neuropsychological tests, including verbal memory. 49 ,54<56 Table 1 describes the study design and findings, which are mixed for all cognitive domains, including verbal memory. Two studies found no support for the critical window hypothesis but found different results with respect to how HT generally impacts cognition. The Three Cities (3C) Study from France found no evidence to support the critical window hypothesis but found evidence for cognitive benefits regardless of timing. 55 Specifically, current use of HT was associated with better performance on tests of verbal fluency, working memory, and psychomotor speed, but these associations did not depend on the timing of initiation. Longer duration of treatment was associated with greater benefits. The Nurses' Health Study (n = 16,514) 57 also found no support for the critical window hypothesis and, in contrast to the 3C Study, actually found that HT was associated with slightly worse cognitive performance with estrogen alone and combination HT. The magnitude of this effect was small; a woman on HT performed as if she were 1 to 2 years older than a woman who was not on HT.
Three other observational studiesVREsearch into MEMory, Brain function, and Estrogen Replacement (REMEMBER) study, 58 Study of Women's Health Across the Nation (SWAN), 49 and Longitudinal Assessment of Women (LAW) study 56 Vfound partial support for the critical window hypothesis. Findings from 486 Australian women aged 70 years or older in the REMEMBER study revealed that early use of HT was associated with enhanced global cognitive function and psychomotor speed. 58 A study of 2,362 women in SWAN found that prior use of HT (ie, generally during early postmenopause) conferred an advantage to performance on immediate and delayed memory outcomes on the East Boston Memory Test. Moreover, initiation before the final menstrual If the mean years since menopause was not provided in the article, the value was estimated as the difference between the current age and the average age at menopause (51 y).
b Fifty-three women were originally recruited into the study, nine dropped out, and six additional women were recruited. Here, all three active treatment groups are combined in the results because they did not differ from one another. Their data are not reported in this table. period conferred cognitive benefits, whereas initiation after the final menstrual period conferred risks. 49 A study of 410 Australian women aged 41 to 79 years who were enrolled in the LAW study found support for the critical window, but only in favor of estrogen alone. The LAW study examined memory performance in two face-to-face assessments 5 years apart. 56 Most women who took HT (80%) were early initiators, with 42% on unopposed estrogen. Early initiation of estrogen alone was associated with a reduced risk of cognitive decline, whereas early start of combination HT was associated with an increased risk for general memory.
In general, findings from observational studies provide mixed findings with respect to the critical window hypothesis. Notable limitations include the use of the East Boston Memory Test, a test on which cognitively healthy women can easily reach maximal performance, in both the Nurses' Health Study and SWAN. With repeated testing on that test, women are more likely to reach maximal performance. The LAW study used a memory test with higher ceiling and greater difficulty that is more sensitive to changes in memory. The 3C Study used transdermal estradiol, which may have cognitive effects different from those of oral estradiol, which became more commonly used in the United States after the WHI. Tables 2 to 5 summarize findings from randomized placebocontrolled trials that included neuropsychological tests of verbal memory as outcomes. These tables are updated from previous reviews. 59, 60 Trials using more experimental measures of verbal memory, such as those used in neuroimaging studies, were not included. In contrast to the observational studies, these trials provide some consistent findings with respect to the timing and use of estrogen alone versus the use of estrogen plus progestin.
RANDOMIZED PLACEBO-CONTROLLED TRIALS OF HT AND VERBAL MEMORY

RANDOMIZED TRIALS OF ESTROGEN ALONE ON VERBAL MEMORY IN YOUNGER PERIMENOPAUSAL AND POSTMENOPAUSAL WOMEN
There have been seven clinical trials of estrogen alone in samples of younger postmenopausal women, defined here as trials where the mean age at randomization is 65 years or younger 61<67 ( Table 2 ). The sample sizes in these studies ranged from 17 to 60, the treatment durations ranged from 21 days to 6 months, and the mean ages of women ranged from 44 to 57 years. Five of the seven studies 61<64,67 found beneficial effects of estrogen on verbal memory compared with placebo, and none found detrimental effects. Notably, one of those trials used a common measure of verbal memory, the California Verbal Learning Test (CVLT), and showed a significant impact on CVLT outcomes (eg, proactive interference, perseverative errors) that are not typically reported in clinical trials and classified as measures of Bexecutive function[ rather than Bverbal memory.[ 67 Furthermore, although estradiol was found not to affect CVLT measures of verbal learning in that trial, the effects of estradiol on short-delay and long-delay free recall (two widely used outcome measures) were not reported and therefore cannot be ascertained. 67 Only one trial investigated cyclic estrogen, and that trial found benefit. 61 Although these findings provide some support for the critical window hypothesis, it is clear that larger studies are needed. The need is particularly high for women who had their ovaries surgically removed at an early age because observational data show that such women are at a 70% increased risk of AD unless they receive estrogen treatment. 68 Table 3 shows findings from five randomized placebocontrolled trials of estrogen alone in samples of women with a mean age older than 65 years at randomization. 53 ,69<72 The sample sizes in these five studies ranged from 38 to 886, the treatment duration ranged from 2 weeks to 5.7 years, and the mean ages ranged from 67 to 76 years. All five trials found neutral effects of estrogen-alone treatment on verbal memory, including the two largest studies: a study of ultralow-dose transdermal estradiol in 417 women treated for 2 years 70 and a study of CEE in 886 women treated for 5.7 years. 53 Overall, these data suggest no negative impact of estrogen alone on verbal memory in older postmenopausal women (see also Schiff et al 73 ). Although some have argued that cyclic estrogen is the most biologically relevant regimen and, therefore, the most likely to be neuroprotective, 74 there is surprisingly little research on cyclic estrogen treatment. Data from placebo-controlled trials in nonhumans provide very compelling evidence that only cyclic estrogen enhances cognition and formation of synapses in the prefrontal cortex. Table 4 shows the results of five trials for combination estrogen-plus-progestogen therapy in samples of women with a mean age younger than 65 years 78<82 and includes two trials that also had an active estrogen-alone arm. 78, 79 The sample sizes in these five studies ranged from 16 to 158, the treatment duration ranged from 2 to 12 months, and the mean ages ranged from 52 to 64 years. Two trials used continuous-combined CEE/MPA (0.625 + 2.5 mg/d), and both found trends (P G 0.06) for a decrease in verbal memory as measured by a modified version of the CVLT. One was the Cognitive Complaints in Early Menopause Trial (COGENT), which involved 180 women with subjective memory complaints who were treated for 4 months 80 ( Fig. 1) . The other was a trial in 66 women who were treated for 1 year. 81 Two trials used estradiol valerate and a progestin, and each found significant improvements in verbal memory. 78, 82 Another trial used estradiol valerate plus norethisterone (0.7 mg/d) in 17 women followed for 6 months. 82 Two trials included both an estrogen-alone arm (each estradiol valerate) and an estrogen-plus-progestin arm. One examined the effects of continuous-combined estradiol valerate (2 mg/d) and dinogest (3 mg/d) on 49 women treated for 3 months and also included an active estradiol-valerate-alone arm; the combination arm showed improvement in verbal memory, whereas the estradiol-valerate-alone arm showed improvement in numerical memory. 78 Another trial in 35 women examined the effects of estradiol valerate (2 mg/d) in combination with oral progesterone (100 mg/d), as well as estradiol valerate alone (2 mg/d), and found no effect on either arm. 79 Together, these studies point out potential differences between types of progestins and, in agreement with WHIMS 10 and WHISCA, 52 potential detrimental effects of CEE/MPA even on younger postmenopausal women. The latter finding argues against beneficial effects early in the critical window for that particular formulation of HT. Although sample sizes are limited, nonYMPA-based progestins may provide some protection and perhaps benefits to verbal memory function if initiated early. There have been no published studies on the effects of cyclic estrogen plus progestin, including cyclic CEE/MPA, on verbal memory in younger postmenopausal women. Larger trials of estrogen alone versus estrogen plus progestin are also needed.
RANDOMIZED TRIALS OF ESTROGEN ALONE ON VERBAL MEMORY IN OLDER WOMEN
75<77
RANDOMIZED TRIALS OF ESTROGEN PLUS PROGESTOGEN ON VERBAL MEMORY IN YOUNGER POSTMENOPAUSAL WOMEN
RANDOMIZED TRIALS OF ESTROGEN PLUS PROGESTOGEN ON VERBAL MEMORY IN OLDER
POSTMENOPAUSAL WOMEN To date, there have been four randomized placebocontrolled trials of combination estrogen-plus-progestogen therapy on neuropsychological measures of verbal memory in older postmenopausal women 52,83<85 (Table 5 ). The quality of these studies is high, with large sample sizes (range, 52-1,416) and long follow-up (up to 4 y). Each of the two trials of CEE/ MPAVthe Heart and Estrogen/progestin Replacement Study (HERS), involving 1,063 women (mean age, 66.8 y; range, 44-79 y), 84 and the WHISCA, involving 1,416 older postmenopausal women (mean age, 74 y; all 65 y or older) 52 V found evidence of a negative impact of treatment on verbal memory. Although both were trends (HERS just missed statistical significance with a P value of 0.06, and WHISCA had P values of 0.01 and 0.02 for two measures), the findings are consistent with evidence from WHIMS 10 and COGENT. 80 NEUROIMAGING STUDIES AND THE CRITICAL WINDOW HYPOTHESIS Functional neuroimaging studies using functional MRI (fMRI) or positron emission tomography provide insights into the effects of HT on brain function in women performing cognitive tasks or at rest. Neuroimaging outcomes are typically more sensitive to drug interventions than are neuropsychological test outcomes. Neuroimaging studies of memory typically involve an encoding condition and a retrieval condition and thereby help to determine what stage of memory HT might affect, encoding items into memory (learning) or retrieving those items from memory. In humans, such studies provide biological plausibility for AD prevention, particularly if HT is shown to positively alter activation in the hippocampus and other brain regions that are functionally impaired HT, hormone therapy; PL, placebo; G3, group 3; G4, group 4; E 2 , estradiol; ET, estrogen therapy; CEE, conjugated equine estrogens; MPA, medroxyprogesterone acetate; T1, P = 0.054 for CVLT short delay and P = 0.06 for CVLT long delay; CVLT, California Verbal Learning Test; BC, black cohosh; RC, red clover; T2, P = 0.056 for CVLT learning and P = 0.02 after controlling for vasomotor symptoms; RAVLT, Rey Auditory Verbal Learning Test.
a G3 is the estradiol-valerate-alone arm. The study also included an open-label arm after the randomized controlled trial, but the results are presented for the blinded arm only.
b G3 is the estradiol-alone arm.
c G3 is the red clover arm, and G4 is the black cohosh arm.
in preclinical and clinical AD. Again, the focus will be neuroimaging studies during verbal memory tasks and relevant structural neuroimaging studies (for a more comprehensive review of neuroimaging studies, see Maki and Dumas 60 ). Initial insights into the neural targets of HT on brain function came from two positron emission tomography studies of the Baltimore Longitudinal Study on Aging. 86, 87 The sample included 32 older women (mean age, 66 y) who were on HT or who have never used HT. It is reasonable to assume that those who were on HT initiated therapy early because that was the typical pattern of HT use in the United States. In both studies, participants completed neuroimaging assessments while resting and while performing a recognition test of words (verbal memory) and figures (visual memory) that they had studied 30 minutes earlier. Results showed that, on neuropsychological tests, users performed better than nonusers on tests of verbal memory and visual memory. On the imaging task, the groups showed differences in brain areas that subserve memory, including the inferior frontal cortex and parahippocampal gyrus. The second study 88 followed that same group of women prospectively during a 2-year interval to look at the effect of HT on the rate of brain aging. Over time, HT users showed increased blood flow to the right hippocampus, right entorhinal cortex, right posterior parahippocampal cortex, other temporal structures, and inferior frontal cortex compared with nonusers. On standardized neuropsychological tests, HT users again showed better memory performance. Importantly, decreased hippocampal activity is associated with an increased risk of Effect of combination CEE/MPA therapy on verbal memory, as measured by the California Verbal Learning Test, in 158 postmenopausal women with a mean age of 52 years. For Group-by-Time interaction, P = 0.054 for short-delay free recall and P = 0.06 for long-delay free recall; women randomized to CEE/MPA declined significantly on short-delay free recall (P = 0.02). The HT-related decline in short-delay and long-delay free recall was 0.63 and 0.68 words, respectively. The CEE/MPA arm is shown in solid black lines, and the placebo arm is shown in dotted lines. Adapted from Maki et al. 80 ; thus, findings of increased hippocampal activity in HT users suggested protection.
A small fMRI study in perimenopausal and early postmenopausal women provided further evidence that HT enhanced the function of the prefrontal cortex during a word retrieval task. 67 Five women randomized to receive transdermal estradiol (0.05 mg/d) and six women randomized to receive placebo (mean age, 51 y) completed the task before and after 12 weeks of therapy. 67 Compared with placebo, estradiol enhanced activation in an area of the prefrontal cortex that is involved in higher-order executive functions such as planning and strategizing. Activation in the prefrontal cortex during a spatial working memory task was also higher in the estradiol group (see also Shaywitz et al 89 and Berent-Spillson et al 90 ). These neuroimaging findings were in agreement with behavioral outcomes on a standardized verbal memory test administered outside the scanner; estradiol treatment did not enhance learning or delayed recall but instead decreased the number of executive errors associated with frontal dysfunction (eg, impulsive errors and errors in updating of working memory). This study therefore suggests that transdermal estradiol enhances prefrontal function during memory tasks in women who were treated during the critical window.
Additional support for the critical window hypothesis came from an fMRI study that examined how early and continued use of HT use affects brain function and memory later in life. 91 The 34 participants (mean age, 60 y) came from the Melbourne Women's Midlife Health Project. Exposure to HT was ascertained using prospectively collected menstrual diary data. All of the active users initiated HT before the final menstrual period. The a priori region of interest was the hippocampus; thus, the study did not examine prefrontal function. Data demonstrated that early and continued use of HT since perimenopause was associated with enhanced verbal recognition and enhanced function of the hippocampus and parahippocampal gyrus later in life.
Together, these neuroimaging findings are notable in light of data from older female monkeys treated with cyclic estradiol, where treatment was associated with enhanced formation of spines in the prefrontal cortex 77 and enhanced performance on tasks mediated by the prefrontal cortex and medial temporal lobe. 75 Studies of the pharmacological suppression of ovarian hormones with the gonadotropin-releasing hormone agonist analog leuprolide acetate provide evidence that loss of estrogen impairs memory and prefrontal function and that add-back estrogen reverses those effects. 92, 93 In addition, some studies have found that the volume of the hippocampus is larger in women who use HT 94<96 and varies depending on the timing of HT such that the shorter is the delay in treatment between menopause and initiation of treatment, the greater is the volume. 95 
INTEGRATED SUMMARY
The critical window hypothesis posits that the effects of HT on cognition depend on the timing of initiation of treatment with respect to age, onset of menopause, or both, and that benefits are limited to early initiation. It is important to recognize that the hypothesis preceded WHIMS and is not simply an after-the-fact explanation of the findings from WHIMS. In light of the literature reviewed above, how does the evidence bear on the hypothesis? In evaluating the evidence, it is important to recognize that the large majority of women in observational studies who used HT initiated treatment during the window. Thus, one can draw on the observational studies to draw conclusions.
As reviewed above, observational studies of ever use of HT, when analyzed using meta-analytic techniques, reliably show a reduced risk of AD. Also as reviewed above, each of the three observational studies that specifically examined timing of initiation, age, or both support the hypothesis in that early use was protective and later use was not or was detrimental. 19, 28, 42 Neuroimaging studies also provide support for the biological plausibility that early initiation of HT is associated with cognitive benefits, based on findings of enhanced hippocampal and prefrontal function and structure. 67, 86, 87, 91, 95, 96 Randomized clinical trials of HT and verbal memory provide preliminary evidence of a beneficial effect of estrogen alone on cognitive function in younger postmenopausal women, 61<64,67 but larger studies are clearly needed. Similarly, small randomized trials of estradiol valerate, in combination with dinogest 78 or norethindrone, 82 provide tentative support for cognitive benefits with those formulations. In contrast, continuous-combined CEE/ MPA does not seem to confer cognitive benefits and may lead to memory decline regardless of timing. 52, 80, 81, 84 Of the five observational studies that examined the timing of HT initiation on cognitive test performance, three provided support, 49, 56, 57 one did not, 55 and one found a slightly negative effect. 54 Overall, the literature suggests that early use of HT might be beneficial for cognitive function when the regimen is not continuous CEE/MPA. An alternative view of available evidence is that it supports Bhealthy cell bias.[ Whereas the critical window hypothesis posits that chronological age, reproductive age, or both are the critical determinants of HT effects, the healthy cell bias posits that women's health is the critical determinant of HT effects. 97 Often good health is confounded with younger age or timing in relation to the menopausal transition; thus, both theories predict cognitive benefits from HT in healthy younger postmenopausal women. However, only the healthy cell bias predicts that baseline cognitive function would predict the extent to which cognitive benefits or risks are observed with HT. Specifically, the healthy cell bias predicts that older women who are Bhealthy[Vwho perform at or above expected levels on cognitive testsVwould benefit from HT even if they are outside the window. Similarly, the healthy cell bias predicts that women whose cognitive performance is poor, regardless of age, would experience the most adverse cognitive effects from HT.
Two findings from WHIMS support the healthy cell bias. First, the degree to which CEE adversely affected cognitive function was greatest among women with the lowest baseline scores on the Modified Mini-Mental State Exam. 98 Second, a structural neuroimaging study involving 1,403 WHIMS participants showed HT-related volume loss in the frontal lobes and hippocampus that was most pronounced among women with low baseline Modified Mini-Mental State Exam scores. 40 In addition, a randomized trial of older postmenopausal women treated with cyclical estradiol and norethindrone found enhanced verbal memory in older women whose cognitive performance was at or above expected levels at baseline, but no benefit in women who were performing below expected levels. 85 Whether certain formulations of HT might benefit certain older women remains unclear, although caution is warranted because WHIMS 10 and WHISCA 52 highlight cognitive risks associated with CEE/MPA.
A top priority in this area of research is to identify a formulation of combination HT that effectively treats hot flashes but is safe for cognition. This need is underscored by findings from WHIMS, 10 WHISCA, 52 HERS, 84 and COGENT 80 showing cognitive risks with continuous-combined CEE/MPA. Initial findings from small randomized trials in younger postmenopausal women indicate that, when combined with estradiol valerate, norethistrone 82 and dinogest 78 enhance verbal memory. Data from a larger sample of older postmenopausal women showed that, when combined with estradiol, cyclic norethindrone had no negative impact on verbal memory overall and might even enhance verbal memory in older women whose cognitive performance was at or above expected levels. 85 It would be helpful to compare the cognitive effects of these progestins head to head. In the future, it is probable that women will have the option of tissue-specific estrogen complexes such as bazedoxifene and CEE, which combine estrogen with a SERM rather than with a progestin. Other pressing research questions pertain to the effects of low-dose HT in light of the increased use of lower doses of oral preparations. SERMs, particularly raloxifene, have been shown to be promising for reducing AD risk. A randomized placebo-controlled clinical trial of raloxifene in 5,386 women followed for 3 years demonstrated that 120 mg reduced the risk of mild cognitive impairment in the preclinical stage of AD but that 60 mg had no effect. 99 The literature on the critical window hypothesis of HT and cognition has evolved in parallel with the literature on the critical window hypothesis of HT and cardiovascular disease (for a review, see Clarkson et al 100 ) . A meta-analysis of clinical trials showed that timing of HT significantly impacted the risk of coronary heart disease events; HT significantly reduced the risk by 32% in women who were less than 10 years from menopause but had no impact on women who were more than 10 years from menopause. 101 A long-term follow-up study of the CEE arm of the WHI showed that, after 10.7 years, the impact of CEE on coronary heart disease events was more favorable in younger postmenopausal women than in older postmenopausal women. 102 CEE significantly reduced the risk of coronary heart disease by 41% among women aged 50 to 59 years at initiation of treatment. 102 Population-based studies with a follow-up of 20 years or longer show that cardiovascular disease risk factors at midlife, including hypertension, insulin resistance, and hypercholesterolemia, are associated with an increased risk of AD later in life.
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In this way, early use of HT might reduce the risk of AD, in part, by lowering cardiovascular risk factors.
Findings from three randomized placebo-controlled clinical trials that are in progress or have been recently completed will provide additional insights into the critical window hypothesis, particularly because their sample sizes in younger women exceed existing studies and the follow-up of each is long. 
CONCLUSIONS
Despite emerging evidence in favor of the critical window hypothesis, HT is not indicated for the treatment of cognitive complaints or for the prevention of cognitive decline or dementia. The findings reviewed above are most relevant to women considering HT for the treatment of vasomotor symptoms. For hysterectomized women, the literature provides tentative support for beneficial cognitive effects with estrogen alone. Such treatment might be especially important for women who had their ovaries removed before the natural onset of menopause. 68 The state of the science is not sufficient to inform women with intact uterus regarding which HT formulation might be cognitively neutral or possibly beneficial. Results from KEEPS will provide important insights into transdermal estradiol and oral combination formulations for these women, and ELITE will provide insights into the cognitive effects of oral estradiol plus a vaginal progestin. Understanding these effects is a top priority in women's health.
